Patient with hyperuricemia and chronic kidney disease is at the doctor: Peculiarities of curation in accordance with Russian recommendations


DOI: https://dx.doi.org/10.18565/therapy.2023.3.129-135

Maksudova A.N., Khalfina T.N., Almukhametova A.I.

Kazan state Medical University of the Ministry of Healthcare of Russia
Abstract. In recent decades, there has been a significant increase in the detectability of asymptomatic hyperuricemia (HU) and gout. The correlation of these conditions with cardiovascular risks, association with arterial hypertension, metabolic syndrome, type 2 diabetes mellitus and CKD determines the high interest of specialists in these pathologies, and at the same time can cause difficulties for clinicians in curation of these patients. That is exactly the combination of HU with a number of comorbid diseases that requires regular monitoring of the level of uric acid in the serum of patients. Currently, there is a fairly clear algorithm for prescribing HU therapy for gout; however, for patients with asymptomatic HU, the choice of treatment remains ambiguous and depends on the presence of certain comorbid diseases. Modern methods of managing patients with both asymptomatic HU and gout include adherence to certain dietary recommendations, control or reduction of body weight, treatment of comorbidities, revision of current therapy with the possible withdrawal of previously prescribed medicines or their replacement with another class of medicines, as well as decision on urate-lowering therapy appointment.
Keywords: screening of hyperuricemia, treatment of hyperuricemia, urate nephropathy, comorbidity, hyperuricemia, chronic kidney disease
Read entire article

Literature

1. Шальнова С.А., Деев А.Д., Артамонова Г.В. с соавт. Гиперурикемия и ее корреляты в российской популяции. Рациональная фармакотерапия в кардиологии. 2014; 10(2): 153–159. [Shalnova S.A., Deev A.D., Artamonov G.V. et al. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF epidemiological study). Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2014; 10(2): 153–159 (In Russ.)]. EDN: SCOUHN.


2. Zhu Y., Pandya B.J., Choi H.K. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012; 125(7): 679–87.e1. https://dx.doi.org/10.1016/j.amjmed.2011.09.033.


3. Амиров Н.Б., Наумова А.Я., Фатыхов Р.Г., Амирова Р.Н. Гиперурикемия: клинические последствия, сердечно-сосудистый риск, современный подход к терапии. Вестник современной клинической медицины. 2022; 15(1): 95–106. [Amirov N.B., Naumova A.Ya., Fatykhov R.G., Amirova R.N. Hyperuricemia: Clinical consequences, cardiovascular risk, modern approach to therapy. Vestnik sovremennoy klinicheskoy meditsiny = The Bulletin of Contemporary Clinical Medicine. 2022; 15(1): 95–106 (In Russ.)]. https://dx.doi.org/10.20969/VSKM. EDN: QOEZSO.


4. Wang Z., Cui T., Ci X. et al. The effect of polymorphism of uric acid transporters on uric acid transport. J Nephrol. 2019; 32(2): 177–87. https://dx.doi.org/10.1007/s40620-018-0546-7.


5. Xu X., Hu J., Song N. et al. Hyperuricemia increases the risk of acute kidney injury: A systematic review and meta-analysis. BMC Nephrol. 2017; 18(1): 27. https://dx.doi.org/10.1186/s12882-016-0433-1.


6. Максудова А.Н., Салихов И.Г., Хабиров Р.А., Халфина Т.Н. Подагра. 3-е изд. М.: Медпресс-информ. 2017; 112 с. [Maksudova A.N., Salikhov I.G., Khabirov R.A., Khalfina T.N. Gout. 3rd ed. Moscow: Medpress-inform. 2017; 112 pp. (In Russ.)]. ISBN: 978-5-00030-444-0.


7. Башкинов Р. А., Батлук Т. И., Мельников Е. С. с соавт. Влияние метаболических нарушений на формирование патологии почек. Южно-Российский журнал терапевтической практики. 2022; 3(2): 7–18. [Bashkinov R.A., Batluk T.I., Melnikov E.S. et al. Influence of metabolic disorders on the development of renal pathology. Yuzhno-Rossiyskiy zhurnal terapevticheskoy praktiki = South Russian Journal of Therapeutic Practice. 2022; 3(2): 7–18 (In Russ.)]. https://dx.doi.org/10.21886/27128156-2022-3-2-7-18. EDN: WAMUSP.


8. Kim Y.J., Oh S.H., Ahn J.S. et al. The crucial role of xanthine oxidase in CKD progression associated with hypercholesterolemia. Int J Mol Sci. 2020; 21(20): 7444. https://dx.doi.org/10.3390/ijms21207444.


9. Миронова О.Ю. Гиперурикемия и поражение почек у пациентов с сердечно-сосудистыми заболеваниями. Терапевтический архив. 2022; 94(12): 1426–1430. [Mironova O.I. Hyperuricemia and kidney damage in patients with cardiovascular disease: A review. Terapevticheskiy arkhiv = Therapeutic Archive. 2022; 94(12): 1426–1430 (In Russ.)]. https://dx.doi.org/10.26442/00403660.2022.12.201999. EDN: HUQVOX.


10. Richette P., Perez-Ruiz F., Doherty M. et al. Improving cardiovascular and renal outcomes in gout: What should we target? Nat Rev Rheumatol. 2014; 10(11): 654–61. https://dx.doi.org/10.1038/nrrheum.2014.124.


11. Чазова И.Е., Жернакова Ю.В., Кисляк О.А. с соавт. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском. Системные гипертензии. 2019; 16(4): 8–21. [Chazova I.E., Zhernakova Ju.V., Kisliak O.A. Consensus on patients with hyperuricemia and high cardiovascular risk treatment. Sistemnyye gipertenzii = Systemic Hypertension. 2019; 16(4): 8–21 (In Russ.)]. https://dx.doi.org/10.26442/2075082X.2019.4.190686. EDN: HSKPCZ.


12. Yang L., Wang B., Ma L., Fu P. Traditional Chinese herbs and natural products in hyperuricemia-induced chronic kidney disease. Front Pharmacol. 2022; 13: 971032. https://dx.doi.org/10.3389/fphar.2022.971032.


13. King C., Lanaspa M.A., Jensen T. et al. Uric acid as a cause of the metabolic syndrome. Contrib Nephrol. 2018; 192: 88–102. https://dx.doi.org/10.1159/000484283.


14. Желябина О.В., Елисеев М.С. Диета при подагре и гиперурикемии. Научно-практическая ревматология. 2017; 55(4): 436–445. [Zhelyabina O.V., Eliseev M.S. Diet in gout and hyperuricemia. Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology. 2017; 55(4): 436–445 (In Russ.)]. https://dx.doi.org/10.14412/1995-4484-2017-436-445. EDN: ZHGSTT.


15. Ben Salem C., Slim R., Fathallah N., Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology (Oxford). 2017; 56(5): 679–88. https://dx.doi.org/10.1093/rheumatology/kew293.


16. Переверзев А.П., Остроумова О.Д. Лекарственно-индуцированные гиперурикемия/подагра. Часть 2: отдельные лекарственные средства, прием которых ассоциирован с повышенным риском развития этих заболеваний. Терапия. 2021; 7(7): 159–169. [Pereverzev A.P., Ostroumova O.D. Drug-induced hyperuricemia/gout. Part 2: CERTAIN medicines, the use of which is associated with an increased risk of developing of these diseases. Terapiya = Therapy. 2021; 7(7): 159–169 (In Russ.)]. https://dx.doi.org/10.18565/therapy.2021.7.159-169. EDN: SOUGAH.


17. Клинические рекомендации. Подагра. Ассоциация ревматологов России. 2018. Доступ: https://legalacts.ru/doc/klinicheskie-rekomendatsii-podagra-utv-minzdravom-rossii/ (дата обращения – 01.04.2023). [Clinical guidelines. Gout. Association of Rheumatologists of Russia. 2020. URL: https://legalacts.ru/doc/klinicheskie-rekomendatsii-podagra-utv-minzdravom-rossii/ (date of access – 01.04.2023) (In Russ.)].


18. Клинические рекомендации. Артериальная гипертензия у взрослых. Общероссийская общественная организация «Российское кардиологическое общество». Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 62. Доступ: https://cr.minzdrav.gov.ru/schema/62_2 (дата обращения – 01.04.2023). [Clinical guidelines. Arterial hypertension in adults. Russian Society of Cardiology. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2020. ID: 62. URL: https://cr.minzdrav.gov.ru/schema/62_2 (date of access – 01.04.2023) (In Russ.)].


19. Клинические рекомендации. Сахарный диабет 2 типа у взрослых. Российская ассоциация эндокринологов. 2019. Доступ: https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/saharnyy_diabet_2_tipa_u_vzroslyh.pdf (дата обращения – 01.04.2023). [Clinical guidelines. Type 2 diabetes. Russian Association of Endocrinologists. 2019. URL: https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/saharnyy_diabet_2_tipa_u_vzroslyh.pdf (date of access – 01.04.2023) (In Russ.)].


20. Клинические рекомендации. Мочекаменная болезнь. Общероссийская общественная организация «Российское общество урологов». Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 7. Доступ: https://cr.minzdrav.gov.ru/schema/7_1 (дата обращения – 01.04.2023). [Clinical guidelines. Kidney stone disease. Russian Society of Urology. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2020. ID: 7. URL: https://cr.minzdrav.gov.ru/schema/7_1 (date of access – 01.04.2023) (In Russ.)].


21. Клинические рекомендации. Хроническая болезнь почек. Ассоциация нефрологов. Рубрикатор клинических рекомендаций Минздрава России. 2021. ID: 469. Доступ: https://cr.minzdrav.gov.ru/schema/469_2 (дата обращения – 01.04.2023). [Clinical guidelines. Chronic kidney disease. Association of Nephrologists. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2021. ID: 469. URL: https://cr.minzdrav.gov.ru/schema/469_2 (date of access – 01.04.2023) (In Russ.)].


22. Zhou M., Huang X., Li R. et al. Association of dietary patterns with blood uric acid concentration and hyperuricemia in Northern Chinese adults. Nutr J. 2022; 21(1): 42. https://dx.doi.org/10.1186/s12937-022-00789-7.


23. Елисеев М.С. Рекомендации Американской коллегии ревматологов (2020 г.) по ведению больных подагрой: что нового и что спорно. Научно-практическая ревматология. 2021; 59(2): 129–133. [Eliseev M.S. ACR management guidelines for the treatment of gout: What’s new and what’s controversial. Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology. 2021; 59(2): 129–133 (In Russ.)]. https://dx.doi.org/10.47360/1995-4484-2021-129-133. EDN: GPVEFY.


24. Головач И.Ю., Егудина Е.Д. Расширение границ уратснижающей терапии: место фебуксостата в лечении подагры. Травма. 2019; 20(2): 20–31. [Golovach I.Yu., Egudina E.D. Expanding the boundaries of urate-reducing therapy: The place of febuxostat in the treatment of gout. Travma = Trauma. 2019; 20(2): 20–31 [ (In Russ.)]. https://dx.doi.org/10.22141/1608-1706.2.20.2019.168017. EDN: EYGEEG.


About the Autors

Adela N. Maksudova, MD, professor of the Department of hospital therapy, Kazan State Medical University of the Ministry of Healthcare of Russia. Address: 420012, Kazan, 49 Butlerova Str. E-mail: adelyamaksudova@gmail.com. ORCID: https://orcid.org/0000-0003-4237-4695
Tamila N. Khalfina, PhD in Medical Sciences, assistant of the Department of hospital therapy, Kazan State Medical University of the Ministry of Healthcare of Russia. Address: 420012, Kazan, 49 Butlerova Str. E-mail: tamila_khalfina@mail.ru. ORCID: https://orcid.org/0000-0003-4537-5730
Alsu I. Almukhametova, attending physician of the Department of hospital therapy, Kazan state Medical University of the Ministry of Healthcare of Russia. Address: 420012, Kazan, 49 Butlerova Str. E-mail: alsu.almukhametova.00@mail.ru. ORCID: https://orcid.org/0009-0008-6644-9739


Similar Articles

Back to Content

Бионика Медиа